Document Detail


Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
MedLine Citation:
PMID:  21405970     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute periods of pulmonary exacerbation are the single most important cause of morbidity in cystic fibrosis patients, and may be associated with a loss of lung function. Intervening prior to the onset of a substantially increased inflammatory response may limit the associated damage to the airways. While a number of biomarker assays based on inflammatory markers have been developed, providing useful and important measures of disease during these periods, such factors are typically only elevated once the process of exacerbation has been initiated. Identifying biomarkers that can predict the onset of pulmonary exacerbation at an early stage would provide an opportunity to intervene before the establishment of a substantial immune response, with major implications for the advancement of cystic fibrosis care. The precise triggers of pulmonary exacerbation remain to be determined; however, the majority of models relate to the activity of microbes present in the patient's lower airways of cystic fibrosis. Advances in diagnostic microbiology now allow for the examination of these complex systems at a level likely to identify factors on which biomarker assays can be based. In this article, we discuss key considerations in the design and testing of assays that could predict pulmonary exacerbations.
Authors:
Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of molecular diagnostics     Volume:  11     ISSN:  1744-8352     ISO Abbreviation:  Expert Rev. Mol. Diagn.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-16     Completed Date:  2011-06-20     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  101120777     Medline TA:  Expert Rev Mol Diagn     Country:  England    
Other Details:
Languages:  eng     Pagination:  197-206     Citation Subset:  IM    
Affiliation:
Molecular Microbiology Research Laboratory, Pharmaceutical Science Division, 150 Stamford Street, Franklin-Wilkins Building, King's College London, London, SE1 9NH, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bacteria / chemistry*
Bacterial Infections / diagnosis,  physiopathology
Biological Markers*
Cystic Fibrosis / diagnosis,  microbiology*,  physiopathology*
Humans
Respiratory Function Tests
Grant Support
ID/Acronym/Agency:
K02 HL105543/HL/NHLBI NIH HHS; R01 HL098084-02/HL/NHLBI NIH HHS; R01 HL098084-03/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identifying biomarkers as diagnostic tools in kidney transplantation.
Next Document:  Lung cancer biomarkers in exhaled breath.